Shanghai Medicilon 관리

관리 기준 확인 3/4

Shanghai Medicilon's CEO is Chunlin Chen, appointed in Jan 2004, has a tenure of 20.83 years. directly owns 11.63% of the company’s shares, worth CN¥550.43M. The average tenure of the management team and the board of directors is 3.8 years and 6 years respectively.

주요 정보

Chunlin Chen

최고 경영자

CN¥925.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	20.8yrs
CEO 소유권	11.6%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	6yrs

최근 관리 업데이트

Recent updates

Shanghai Medicilon Inc. (SHSE:688202) Might Not Be As Mispriced As It Looks

Sep 27

Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?

Jun 07

Market Cool On Shanghai Medicilon Inc.'s (SHSE:688202) Revenues Pushing Shares 27% Lower

Apr 25

CEO

Chunlin Chen (62 yo)

20.8yrs

테뉴어

CN¥925,000

보상

Dr. Chun-Lin Chen, Ph D Co-founded Shanghai Medicilon, Inc. in 2004 and serves as its Chief Executive Officer. Dr. Chen Co-founded Medicilon-MPI Preclinical Research Shanghai, LLC.(also known as Medicilon...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chunlin Chen	Co-Founder	20.8yrs	CN¥925.00k	11.63% CN¥ 550.4m
Binbin Liu	Chief Financial Officer	7.9yrs	CN¥633.60k	0.016% CN¥ 734.3k
Shuangqing Peng	Chief Scientific Officer & Core Technical Staff	7.4yrs	CN¥909.80k	0.034% CN¥ 1.6m
Jinna Cai	Chief Commercial Officer	3.8yrs	CN¥861.40k	0.023% CN¥ 1.1m
Chao Xue	Board Secretary	3yrs	CN¥504.00k	0.0032% CN¥ 150.6k
Donghua Zhang	Head of Accounting Department	no data	데이터 없음	데이터 없음
Jiang Xu	Manager of Human Resources Department	no data	데이터 없음	데이터 없음
Jian Liu	President of Drug Discovery Division	no data	데이터 없음	데이터 없음
Haizhou Zhang	President of Preclinical R&D Unit	less than a year	데이터 없음	데이터 없음
Qingcong Lin	President of Medicilon USA Corp	less than a year	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 관리: 688202's management team is considered experienced (3.8 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chunlin Chen	Co-Founder	no data	CN¥925.00k	11.63% CN¥ 550.4m
Jinna Cai	Chief Commercial Officer	no data	CN¥861.40k	0.023% CN¥ 1.1m
Jinzhang Chen	Chairman of the Board	no data	데이터 없음	12.24% CN¥ 579.6m
Changqing Lin	Director	9.3yrs	데이터 없음	4.09% CN¥ 193.9m
Weichun Jin	Supervisor	8.3yrs	데이터 없음	데이터 없음
Guoxing Chen	Board Director	9.3yrs	데이터 없음	3.65% CN¥ 172.7m
Dawei Ma	Independent Director	3yrs	CN¥120.00k	데이터 없음
Weidong Lai	Independent Director	3yrs	CN¥120.00k	데이터 없음
Jinye Xu	Independent Director	6yrs	CN¥120.00k	데이터 없음
Lei Wang	Employee Representative Supervisor	3yrs	CN¥105.50k	데이터 없음

6.0yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: 688202's board of directors are considered experienced (6 years average tenure).

Shanghai Medicilon 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Shanghai Medicilon Inc., Annual General Meeting, May 17, 2024

Medicilon Appoints Dr. Qingcong Lin as President of Medicilon Usa Corp

Medicilon Appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit

Medicilon Appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit

Less than half of directors are independent

No independent directors

Recent updates

Third quarter 2024 earnings released: CN¥0.44 loss per share (vs CN¥0.41 loss in 3Q 2023)

New major risk - Share price stability

Shanghai Medicilon Inc. to Report Q3, 2024 Results on Oct 31, 2024

Shanghai Medicilon Inc. (SHSE:688202) Might Not Be As Mispriced As It Looks

Second quarter 2024 earnings released: CN¥0.24 loss per share (vs CN¥0.53 profit in 2Q 2023)

Shanghai Medicilon Inc. to Report First Half, 2024 Results on Aug 20, 2024

Is Shanghai Medicilon (SHSE:688202) Weighed On By Its Debt Load?

New minor risk - Share price stability

Market Cool On Shanghai Medicilon Inc.'s (SHSE:688202) Revenues Pushing Shares 27% Lower

Shanghai Medicilon Inc., Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Shanghai Medicilon Inc. to Report Q1, 2024 Results on Apr 29, 2024

New minor risk - Share price stability

Medicilon Appoints Dr. Qingcong Lin as President of Medicilon Usa Corp

Full year 2023 earnings released: CN¥0.24 loss per share (vs CN¥2.78 profit in FY 2022)

Investor sentiment deteriorates as stock falls 19%

Medicilon Appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit

Medicilon Appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: CN¥0.41 loss per share (vs CN¥0.95 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.53 (vs CN¥0.70 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥3.89 (vs CN¥3.25 in FY 2021)

Investor sentiment improves as stock rises 27%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥1.33 (vs CN¥0.79 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.98 (vs CN¥0.78 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥1.24 (vs CN¥0.73 in 1Q 2021)

No independent directors

Full year 2021 earnings released: EPS: CN¥4.55 (vs CN¥2.09 in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Shanghai Medicilon Inc. announced that it expects to receive CNY 2.16 billion in funding

Third quarter 2021 earnings released: EPS CN¥1.10 (vs CN¥0.45 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥1.09 (vs CN¥0.49 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥2.09 (vs CN¥1.36 in FY 2019)

New 90-day high: CN¥296

New 90-day high: CN¥201

New 90-day low: CN¥141

New 90-day high: CN¥185

New 90-day high - CN¥162

New 90-day high - CN¥152

Shanghai Medicilon Inc. to Report First Half, 2020 Results on Aug 18, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령